🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
13/04/2015 0,5100 USD
13/01/2015 0,4900 USD
10/10/2014 0,4200 USD
11/07/2014 0,4200 USD
11/04/2014 0,4200 USD
13/01/2014 0,4000 USD
10/10/2013 0,4000 USD
11/07/2013 0,4000 USD
11/04/2013 0,4000 USD
11/01/2013 0,4000 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/12/2025 226,41 226,84 221,91 223,67 -1,66% 2,18% 6.405.900
15/12/2025 224,24 228,30 223,56 227,45 +1,85% 2,11% 5.971.900
12/12/2025 223,69 223,82 221,10 223,32 -0,29% 1,22% 5.467.600
11/12/2025 225,54 225,96 222,24 223,98 -0,53% 1,65% 4.170.600
10/12/2025 225,00 225,98 221,00 225,18 +0,98% 2,21% 8.735.200
09/12/2025 223,89 224,82 220,23 222,99 -0,06% 2,05% 4.267.900
08/12/2025 226,08 226,12 222,39 223,12 -1,31% 1,65% 4.006.100
05/12/2025 228,93 229,25 225,05 226,08 -1,15% 1,83% 3.985.200
04/12/2025 230,11 230,94 227,59 228,71 -0,66% 1,46% 3.732.900
03/12/2025 224,84 230,79 224,52 230,24 +2,62% 2,79% 4.872.900
02/12/2025 224,82 226,63 223,11 224,37 -0,33% 1,57% 5.096.700
01/12/2025 227,19 229,49 223,98 225,11 -1,14% 2,43% 5.208.300
28/11/2025 226,85 228,09 225,51 227,70 +0,02% 1,14% 2.655.600
26/11/2025 232,04 232,48 226,64 227,66 -1,79% 2,52% 5.920.800
25/11/2025 230,32 234,08 230,31 231,80 +1,00% 1,64% 7.134.100
24/11/2025 236,00 237,62 228,48 229,51 -2,87% 3,87% 10.225.900
21/11/2025 230,55 238,01 230,14 236,28 +2,98% 3,41% 8.017.600
20/11/2025 233,26 234,95 228,00 229,45 -1,49% 2,98% 4.283.600
19/11/2025 233,54 238,15 230,36 232,91 -0,41% 3,34% 7.618.400
18/11/2025 235,00 237,19 232,11 233,87 -0,06% 2,16% 6.232.600
17/11/2025 233,26 235,35 229,23 234,00 +0,71% 2,62% 5.023.100
14/11/2025 233,61 235,00 230,32 232,36 +0,03% 2,00% 5.461.500
13/11/2025 233,74 239,29 232,16 232,29 -0,40% 3,05% 7.968.500
12/11/2025 225,40 234,00 225,29 233,23 +3,58% 3,86% 8.583.200
11/11/2025 219,00 225,42 219,00 225,17 +2,95% 2,93% 4.802.400
10/11/2025 217,00 219,86 216,15 218,71 -0,21% 1,71% 4.530.800
07/11/2025 219,31 220,99 217,09 219,16 +0,05% 1,78% 4.647.900
06/11/2025 215,89 219,68 215,65 219,04 +1,05% 1,87% 6.615.300
05/11/2025 215,74 217,43 212,60 216,77 +0,41% 2,24% 4.928.200
04/11/2025 212,37 217,08 212,37 215,89 +1,85% 2,22% 6.184.000